CYAD Celyad SA

-0.09  -1%
Previous Close 14.31
Open 13.97
Price To Book 2.71
Market Cap 169,820,132
Shares 11,942,344
Volume 12,962
Short Ratio
Av. Daily Volume 10,535

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data did not meet primary endpoint
C-Cure - Chart 1 trial
Chronic Heart Failure secondary to ischemic cardiomyopathy
Phase 1 update at EHA June 15, 2019. 21% ORR.
Various cancers - solid and hematologic cancers
Phase 1 data to presented at ESMO noted 1/6 partial responses and three with stable disease.
CYAD-101 - alloSHRINK
Colorectal cancer
Phase 1 data to presented at ESMO July 2019 noted 1/9 partial responses, 6/9 stable disease.
Colorectal cancer
Phase 1 initial data from Cohort 4 due by end of 2019.
CYAD-01 and chemotherapy (DEPLETHINK)
AML or myelodysplastic syndrome (MDS)
Phase 1 trial to commence early 2020 with data due mid-2020.
Relapsed/refractory Acute myeloid leukemia (AML) and Myelodysplastic Syndrome (MDS)

Latest News

  1. Celyad Sees Hammer Chart Pattern: Time to Buy?
  2. The Daily Biotech Pulse: FDA Approves Karyopharm's Blood Cancer Treatment, Grifols' Immunodeficiency Drug; ESMO, ISTH Conferences In The Spotlight
  3. Celyad Presents Update on Autologous & Allogeneic NKG2D-based CAR-T Therapies in Solid Tumors
  4. Celyad to Host Conference Call to Review Clinical Update from ESMO 21st World GI Congress
  5. The Daily Biotech Pulse: Celyad To Advance Leukemia Drug To Clinical Trial, Positive Data For Teva's Migraine Drug
  6. Celyad Announces Strategic Updates to the Autologous r/r AML and MDS Program
  7. Celyad SA Sees Hammer Chart Pattern: Time to Buy?
  8. Celyad Presents Clinical Update for CYAD-01 at 24th Congress of the European Hematology Association
  9. Celyad to Participate in Upcoming June 2019 Conferences
  10. Celyad to Present Data at 24th Congress of the European Hematology Association
  11. Celyad Announces First Quarter 2019 Financial Results and Recent Business Highlights
  12. Celyad Announces May 2019 Investor Conference Schedule
  13. Celyad to Present Update on allogeneic and autologous NKG2D-based CAR-T Candidates in Refractory mCRC at ESMO 21st World GI Congress
  14. Celyad Announces April 2019 Investor Conference Schedule
  15. Celyad Reports Business Update and Full Year 2018 Financial and Operating Results
  16. Celyad Appoints Filippo Petti as Chief Executive Officer
  17. Celyad’s 2019 R&D Day Highlights shRNA Platform and Pipeline of Next-generation NKG2D-based and Off-the-Shelf Non-gene Edited CAR-T Candidates
  18. Celyad to Host R&D Day and Webcast on Monday, March 18 in New York City
  19. Celyad Appoints Anne Moore as Vice President Corporate Strategy
  20. Celyad Announces February and March 2019 Investor Conference Schedule